These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 23637377)

  • 1. Five-year data from the REFLEX study: a different interpretation.
    Abeles AM
    J Rheumatol; 2013 May; 40(5):732. PubMed ID: 23637377
    [No Abstract]   [Full Text] [Related]  

  • 2. Dr. Keystone, et al, reply.
    J Rheumatol; 2013 May; 40(5):732-3. PubMed ID: 23767071
    [No Abstract]   [Full Text] [Related]  

  • 3. Comment on: Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.
    Belmonte Serrano MA; Pincus T
    Rheumatology (Oxford); 2010 Sep; 49(9):1795-6; author reply 1796-7. PubMed ID: 20484342
    [No Abstract]   [Full Text] [Related]  

  • 4. The updated guidelines on the use of rituximab in rheumatoid arthritis.
    Lopez-Olivo MA; Tayar JH; Suarez-Almazor ME
    Rheumatology (Oxford); 2011 Dec; 50(12):2153-4. PubMed ID: 21546350
    [No Abstract]   [Full Text] [Related]  

  • 5. BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis.
    Bukhari M; Abernethy R; Deighton C; Ding T; Hyrich K; Lunt M; Luqmani R; Kiely P; Bosworth A; Ledingham J; Ostör A; Gadsby K; McKenna F; Finney D; Dixey J;
    Rheumatology (Oxford); 2011 Dec; 50(12):2311-3. PubMed ID: 21546351
    [No Abstract]   [Full Text] [Related]  

  • 6. TNF-alpha antagonists and other recombinant proteins for the treatment of rheumatoid arthritis.
    Brasington R
    J Hand Surg Am; 2009 Feb; 34(2):349-50. PubMed ID: 19135810
    [No Abstract]   [Full Text] [Related]  

  • 7. [Pharmacotherapy of rheumatoid arthritis in the era of genetically engineered biological preparations].
    Nasonov EL
    Ter Arkh; 2007; 79(5):5-8. PubMed ID: 17672066
    [No Abstract]   [Full Text] [Related]  

  • 8. Putting new disease-modifying antirheumatic drugs into perspective.
    Saseen JJ
    Pharmacotherapy; 2007 Dec; 27(12):1609-10. PubMed ID: 18041880
    [No Abstract]   [Full Text] [Related]  

  • 9. Successful rapid rituximab desensitization for hypersensitivity reactions to monoclonal antibodies in a patient with rheumatoid arthritis: a remarkable option.
    Abadoglu O; Epozturk K; Atayik E; Kaptanoglu E
    J Investig Allergol Clin Immunol; 2011; 21(4):319-21. PubMed ID: 21721382
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy of rituximab in patients with rheumatoid arthritis refractory or with contra-indication to anti-tumor necrosis factor-alpha drugs in daily practice: an open label observational study.
    Assous N; Gossec L; Dougados M; Kahan A; Allanore Y
    Clin Exp Rheumatol; 2007; 25(3):504. PubMed ID: 17631755
    [No Abstract]   [Full Text] [Related]  

  • 11. [Proposal for biologic drugs therapy in rheumatoid arthritis].
    Curković B; Babić-Naglić D; Morović-Vergles J; Anić B; Grazio S; Kaliterna DM; Hanih M; Novak S
    Reumatizam; 2010; 57(1):29-35. PubMed ID: 20941938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adalimumab for rheumatoid arthritis?
    Ebell M; Kripke C
    Am Fam Physician; 2006 Feb; 73(3):435-6. PubMed ID: 16479667
    [No Abstract]   [Full Text] [Related]  

  • 13. [Treatment of rheumatoid arthritis by inhibition of tumor necrosis factor with infliximab or etanercept].
    Verhoeven AC; Boers M
    Ned Tijdschr Geneeskd; 2001 Nov; 145(47):2294-5. PubMed ID: 11760611
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of tumor necrosis factor-alpha inhibitors on lung lesions with rheumatoid arthritis.
    Inoue K; Takano H; Yanagisawa R; Yoshikawa T
    Chest; 2003 Jul; 124(1):413-4; author reply 414. PubMed ID: 12853558
    [No Abstract]   [Full Text] [Related]  

  • 15. Graves' disease in a patient with rheumatoid arthritis during treatment with anti-tumor necrosis factor-alpha.
    van Lieshout AW; Creemers MC; Radstake TR; Elving LD; van Riel PL
    J Rheumatol; 2008 May; 35(5):938-9. PubMed ID: 18464319
    [No Abstract]   [Full Text] [Related]  

  • 16. Active tuberculosis in a patient with rheumatoid arthritis treated with tumor necrosis factor-alpha inhibitor.
    Fuchs I; Abu-Shakra M; Gelfer E; Smoliakov A; Ben-Haroch D; Horowitz J; Avnon LS
    Isr Med Assoc J; 2010 Sep; 12(9):579-81. PubMed ID: 21287806
    [No Abstract]   [Full Text] [Related]  

  • 17. Knee tuberculosis under rituximab therapy for rheumatoid arthritis.
    Ottaviani S; Tiendrebeogo J; Choudat L; Gill G; Palazzo E; Meyer O; Dieudé P
    Joint Bone Spine; 2013 Jul; 80(4):435-6. PubMed ID: 23238006
    [No Abstract]   [Full Text] [Related]  

  • 18. Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab.
    Gelinck LB; Teng YK; Rimmelzwaan GF; van den Bemt BJ; Kroon FP; van Laar JM
    Ann Rheum Dis; 2007 Oct; 66(10):1402-3. PubMed ID: 17881666
    [No Abstract]   [Full Text] [Related]  

  • 19. When first line therapy for AA-amyloidosis secondary to rheumatoid arthritis fails: a correspondence.
    Burkart J; Benson DM
    Joint Bone Spine; 2013 Mar; 80(2):229-30. PubMed ID: 23022420
    [No Abstract]   [Full Text] [Related]  

  • 20. Biologic therapy for rheumatoid arthritis.
    Klippel JH
    N Engl J Med; 2000 Nov; 343(22):1640-1. PubMed ID: 11096174
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.